Evidence map›Paper›PMID 40647546›Full record

ArticleCancers2025

Multi-Cancer Genome Profiling for Neurotrophic Tropomyosin Receptor Kinase (NTRK) Fusion Genes: Analysis of Profiling Database of 88,688 Tumors.

Hinano Nishikubo, Kyoka Kawabata, Saki Kanei, Rika Aoyama, Dongheng Ma, Tomoya Sano, Daiki Imanishi, Takashi Sakuma, Koji Maruo, Canfeng Fan and 2 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hinano NishikuboMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Kyoka KawabataMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Saki KaneiMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Rika AoyamaMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Dongheng MaMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Tomoya SanoMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Daiki ImanishiMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Takashi SakumaMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Koji MaruoMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Canfeng FanMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Yurie YamamotoMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Masakazu YashiroMolecular Oncology and Therapeutics, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.ORCID 0000-0001-5743-7228

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

fusionmulti-cancer genome profilingNTRK geneRNA sequencingsolid tumors

Identifiers

PMID40647546
PMCPMC12248648

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.